(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Response Uncovered: Disentangling the Secrets of the Universe - 2'Malcolm in the Middle' reboot releases 1st trailer, reuniting Frankie Muniz and Bryan Cranston: Watch here
- 3Dependable Savvy Locks to Update Your Home Security
- 4Israel faces tough choices over haredi draft exemptions, legal expert warns
- 54 Jeep Models: Dominating Execution and Flexibility for Each Experience
- Key Business Regulations to Consider While Arranging Your Independent venture
- Iran-backed militias reassert power in Iraq, proving the Islamic axis is still standing
- Public Parks in the USA
- Figure out How to Establish a long term connection with Your Handshake
- More than 3 million eye drops have been recalled from CVS, Walgreens and other national retailers. How to check if yours are safe
- Polls open in tense Uganda election amid widespread delays
- Gulf countries continue to face Iran attacks as criticial energy infrastructure at risk
- Manual for 6 well known Amusement Park
- Who is Artemis? Meet the Greek goddess who inspired NASA's return to the moon
